chief development officer

Pierre has over 30 years in drug development. He was formerly at Hoffmann-La Roche, where he was Life-Cycle Leader and has leading biotech startups, with responsibility for all aspects of drug development, from the laboratory bench, through clinical trials, and into the market.  He holds a Ph.D. in Molecular Biology from University of Basel.

Pierre leads a seasoned drug development team: 

• Prof. Klaus Kutz M.D: former Head of Clinical Pharmacology at both Novartis and Sanofi with oncology expertise. 
• Rudolf Hausmann, PhD: former Roche and Viopas expert in CMC
• Karl Burgin, PhD: former Roche and seasoned regulatory affairs expert

They have over 120 years experience in bringing new drugs to market, including Tamiflu (oseltamivir), CellCept (mycofenelate mofetil), Dilatrend (carvedilol), Sandimmun Neoral (cyclosporine), Sandostatin (octreotide), Lamisil (terbinafine) or Plavix (clopidogrel).